Zack Gong

Zack focuses his practice on the representation of public and private pharmaceutical, biotechnology, and other life sciences companies with respect to a variety of intellectual property-based commercial transactions. He advises companies on license agreements, research collaborations and development agreements, manufacturing, distribution, and supply agreements, as well as intellectual property matters within corporate transactions such as public offerings and mergers and acquisitions. 

Zack is a native Mandarin speaker and is fluent in English. 

Representative Matters:

• Represented Otsuka Pharmaceutical in its exclusive global licensing agreement (excluding Greater China) with Harbour BioMed for the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager under development by Harbour BioMed (2025)
• Represented Earendil Labs (company affiliated with Helixon Therapeutics) in its worldwide exclusive license agreement with Sanofi for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases (2025)
• Represented Zai Lab in its exclusive sublicense with Zenas to develop, manufacture and commercialize Zenas’ thyroid eye disease programs, including ZB001, an insulin-like growth factor-1 receptor (anti-IGF-1R) monoclonal antibody in Greater China (2025)
• Represented Windward Bio (NewCo) in its license agreement with Harbour BioMed and Sichuan Kelun Biotech BioPharmaceutical for HBM9378/SKB378, an anti-thymic stromal lymphopoietin (TSLP) fully human monoclonal antibody (2025)
• Represented Aclaris Therapeutics in its exclusive license agreement with Biosion for worldwide rights (excluding Greater China) to BSI-045B, a potential First-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R (2024)
• Represented Laekna in its clinical collaboration with Eli Lilly and Company to accelerate the development of LAE102, a novel ActRIIA mAb as a treatment for obesity (2024)
• Represented a clinical-stage biotechnology company specializing in innovative radiopharmaceuticals in an exclusive license agreement with a leading biotechnology company granting the latter the right to commercialize the late-stage radiotherapy AlphaMedix (212Pb-DOTAMTATE) worldwide (2024)
• Represented Instil Bio (NewCo) in its in-licensing agreement with ImmuneOnco Biopharmaceuticals for ex-China development and commercial rights to ImmueOnco’s proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M (2024)
• Represented Belenos Biosciences in its exclusive license agreement with Keymed Biosciences for global research, development, registration, manufacturing and commercialization of Keymed Biosciences’ drug candidates, CM512 and CM536, excluding the Greater China region (2024)
• Represented Jiangsu Hengrui Pharmaceuticals (Hengrui) on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco (Hercules), a newly established Delaware company (2024)
• Represented MediLink in its worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors (2023)
• Represented Allay Therapeutics in its license agreement to provide Maruishi Pharmaceutical with exclusive rights in Japan to develop and commercialize Allay’s lead investigation drug candidate – ATX101 – and other ultra-sustained analgesic implantable drug candidates for acute pain (2023)
• Represented SystImmune in its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1 (2023)
• Represented Rona Therapeutics in its collaboration with Keymed Biosciences to jointly discover and develop first-in-class siRNA Therapeutics for Glomerulonephritisbinder (2023)
• Represented JW Therapeutics in its license and collaboration agreement with Juno Therapeutics for the research, development, manufacturing and commercialization of new cellular therapy products DLL3 in Greater China (2022)
• Represented IASO Biotherapeutics in an exclusive and worldwide out-licensing agreement with Cabaletta Bio (Nasdaq: CABA) to develop, manufacture and commercialize fully-human CD19 binder (2022)
• Represented Zai Lab (Nasdaq: ZLAB; HKEX: 9688) in its exclusive collaboration and license agreement with Seagen for the development and commercialization of TIVDAK® in Greater China (2022)
• Represented Horizon Therapeutics in its agreement to be acquired by Amgen at approximately $28 billion (2022)
• Represented Apollo Endosurgery in its agreement to be acquired by Boston Scientific (2022)
• Represented Sixth Street in its strategic investment in Blueprint Medicines (2022)
• Represented Hutchmed Limited (Nasdaq: HCM) in its commercial license agreement with GenScript (2021)
• Represented Hutchmed Limited in its commercial supply and collaboration arrangement with AstraZeneca for Savolitinib in China (2021)
• Represented Hutchmed Limited in its technology transfer and supply agreement with Epizyme Inc. (2021)
• Represented LianBio (Nasdaq: LIAN) in its exclusive license agreement with MyoKardia for the rights to develop and commercialize mavacamten in Greater China and other Asian markets (2020)
• Represented LianBio in its strategic platform collaboration agreement with Pfizer (2020)
• Represented CASI Pharmaceuticals, Inc. in its license and development agreement with Cleave Therapeutics for the rights to develop and commercialize a novel VCP/p97 inhibitor in Greater China (2020)
• Represented Janssen Biotech Inc. (J&J affiliate) in its research collaboration agreement with National University of Singapore (2020)